Quotes 5-day view Delayed Nasdaq
10/20/2020
10/21/2020
10/22/2020
10/23/2020
10/26/2020
Date
80.7(c)
81.74(c)
83.63(c)
84.47(c)
84.1(c)
Last
733 292
703 205
1 091 949
854 083
352 126
Volume
+1.38% +1.29% +2.31% +1.00% -0.44% Change
Sales 2020
876 M - -
Net income 2020
30,0 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
122x
Yield 2020
-
Sales 2021
1 001 M - -
Net income 2021
76,4 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
48,7x
Yield 2021
-
Capitalization
3 612 M 3 612 M -
Capi. / Sales 2020
4,12x
Capi. / Sales 2021
3,61x
Nbr of Employees
2 780
Free-Float
81,3%
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in...
Notations Surperformance© of Omnicell, Inc.
Trading Rating : Investor Rating :
All news about OMNICELL, INC.
News in other languages on OMNICELL, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends OMNICELL, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
8
Average target price
80,63 $
Last Close Price
84,47 $
Spread / Highest target
18,4%
Spread / Average Target
-4,55%
Spread / Lowest Target
-30,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
